Tech Company Financing Transactions
Tacit Therapeutics Funding Round
KdT Ventures, Civilization Ventures and Michigan Capital Network joined a $19 million Series A funding round for Tacit Therapeutics. The funding round was recorded on 3/9/2026.
Transaction Overview
Company Name
Announced On
3/9/2026
Transaction Type
Venture Equity
Amount
$19,000,000
Round
Series A
Investors
Proceeds Purpose
The new capital will support advancement of Tacit's lead neurological programs toward IND-enabling studies, and the expansion to additional therapeutic areas.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
329 Oyster Point Boulevard, 3rd Floor
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
We're redirecting the flow of genetic information to deliver on the promise of gene therapy. Our mission is to overcome the barriers that have held back genetic medicine by creating the first broadly-applicable and non-immunogenic way to treat hundreds of diseases. Tacit Therapeutics is a San Francisco biotechnology company that was formed to realize the potential of gene therapy. Team Tacit was brought together by a core insight: human cells continuously patch together genetic sequences through a process called splicing.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Nelles
Browse more venture capital transactions:
Prev: 3/9/2026: Kast venture capital transaction
Next: 3/9/2026: Saltz venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs